- Home
- AMPX vs YMAB Comparison
AMPX vs YMAB Comparison
Compare AMPX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- YMAB
- Stock Information
- Founded
- AMPX 2008
- YMAB 2015
- Country
- AMPX United States
- YMAB United States
- Employees
- AMPX N/A
- YMAB N/A
- Industry
- AMPX Industrial Machinery/Components
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- YMAB Health Care
- Exchange
- AMPX Nasdaq
- YMAB Nasdaq
- Market Cap
- AMPX 261.0M
- YMAB 270.5M
- IPO Year
- AMPX N/A
- YMAB 2018
- Fundamental
- Price
- AMPX $3.01
- YMAB $5.72
- Analyst Decision
- AMPX Strong Buy
- YMAB Strong Buy
- Analyst Count
- AMPX 8
- YMAB 10
- Target Price
- AMPX $8.63
- YMAB $21.10
- AVG Volume (30 Days)
- AMPX 3.0M
- YMAB 542.6K
- Earning Date
- AMPX 03-20-2025
- YMAB 03-04-2025
- Dividend Yield
- AMPX N/A
- YMAB N/A
- EPS Growth
- AMPX N/A
- YMAB N/A
- EPS
- AMPX N/A
- YMAB N/A
- Revenue
- AMPX $17,480,000.00
- YMAB $84,553,000.00
- Revenue This Year
- AMPX $132.63
- YMAB $6.41
- Revenue Next Year
- AMPX $214.27
- YMAB $18.15
- P/E Ratio
- AMPX N/A
- YMAB N/A
- Revenue Growth
- AMPX 196.22
- YMAB N/A
- 52 Week Low
- AMPX $0.61
- YMAB $5.60
- 52 Week High
- AMPX $4.21
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- AMPX 43.80
- YMAB 35.08
- Support Level
- AMPX $3.28
- YMAB $5.60
- Resistance Level
- AMPX $3.65
- YMAB $6.57
- Average True Range (ATR)
- AMPX 0.28
- YMAB 0.38
- MACD
- AMPX -0.06
- YMAB 0.10
- Stochastic Oscillator
- AMPX 8.49
- YMAB 11.43
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.